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Serotonin syndrome is a potentially life-threatening condition associated with increased serotonergic activity in the central nervous
system. It is classically associatedwith the simultaneous administration of two serotonergic agents, but it can occur after initiation of
a single serotonergic drug or increasing the dose of a serotonergic drug in individuals who are particularly sensitive to serotonin.We
describe a case of serotonin syndrome that occurred after ingestion of higher than prescribed doses of lamotrigine and aripiprazole,
in addition to cocaine abuse.The diagnosis was established based onHunter toxicity criteria and severity was classified as mild.The
features of this syndrome resolved shortly after discontinuation of the offending agents. Serotonin syndrome is characterized by
mental status changes, autonomic hyperactivity, and neuromuscular abnormalities along a spectrum ranging from mild to severe.
Serotonin syndrome in our patient was most likely caused by the pharmacokinetic and pharmacodynamic interactions between
lamotrigine, aripiprazole, and cocaine leading to increased CNS serotonergic activity.
1. Introduction
Serotonin syndrome is a potentially life-threatening condi-
tion associated with increased serotonergic activity in the
central nervous system (CNS). It is classically associated with
the simultaneous administration of two serotonergic agents,
but it can occur after initiation of a single serotonergic drug or
increasing the dose of a serotonergic drug in individuals who
are particularly sensitive to serotonin [1–4]. Lamotrigine,
aripiprazole, and cocaine have traditionally not been associ-
ated with this syndrome and none of them have strong sero-
tonergic activity by themselves. An extensive literature search
on PubMed did not yield any case description of serotonin
syndrome induced by lamotrigine, aripiprazole, and cocaine
alone or in combination. Also, UpToDate, Micromedex, and
Epocrates do not list this syndrome as an adverse effect for
any of these agents. We hypothesize that pharmacokinetic
and pharmacodynamic interactions between these agents
were responsible for inducing serotonin syndrome in our
patient.
2. Case Presentation
A 24-year-old Caucasian female with a psychiatric history
of bipolar disorder, posttraumatic stress disorder (PTSD),
and cocaine abuse was admitted for nausea, dizziness, and
jitteriness that started after intentional ingestion of 4 gm of
lamotrigine and 80mg of aripiprazole, in addition to cocaine
abuse. On admission, she was alert, oriented, and afebrile
but was noted to be diaphoretic, tachycardic, and in mild
distress due to nausea and vertigo. Her pupils were equal,
round, and reactive to light but horizontal nystagmus was
present in both eyes. Neurologic examinationwas remarkable
for hyperreflexia in bilateral lower extremities with inducible
patellar and ankle clonus but normal sensation and strength.
Laboratory studies were remarkable only for mildly elevated
liver enzymes that normalized within 24 hours. Urine was
positive for codeine, cocaine, and lamotrigine. On the date
of admission, blood level of lamotrigine was 7.5mcg/mL
(reference 3–14) and that of aripiprazole was 760 ng/mL
(reference 0–870), both being within normal limits.
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Based on the Hunter criteria, she was diagnosed with
serotonin syndrome with severity classified as mild. Other
differential diagnoses were ruled out based on clinical
grounds andmedication history. Shewasmanaged by discon-
tinuing lamotrigine and aripiprazole andwith oral lorazepam
for symptom control for a period of 24 hours. During the
hospital stay, her tachycardia and nystagmus resolved over
24 hours. The clonus and hyperreflexia improved and later
resolved over 48 hours. Her symptoms of nausea, dizziness,
jitteriness and diaphoresis also resolved within 24 hours. Her
skin remained completely normal during and after hospital
stay; this was monitored because of concern for Stevens-
Johnson syndrome with lamotrigine.
After the resolution of features consistent with sero-
tonin syndrome, the patient was started on divalproex and
risperidone for bipolar disorder and PTSD. On follow-up,
her psychiatric conditions have been well managed. She has
continued to abuse cocaine but has not developed similar
symptoms or signs again.
3. Discussion
Serotonin syndrome is characterized by mental status
changes, autonomic hyperactivity, andneuromuscular abnor-
malities along a spectrum ranging from mild to severe [1, 5–
7]. Mental status changes can include anxiety, agitated delir-
ium, restlessness, and disorientation. Autonomic manifes-
tations can include diaphoresis, tachycardia, hyperthermia,
hypertension, nausea, vomiting, and diarrhea [1, 5, 6]. Neu-
romuscular hyperactivity usually manifests as hyperreflexia
and clonus most pronounced in the lower extremities but
may present as muscle rigidity and bilateral Babinski sign
[1]. Laboratory abnormalities in severe cases can include
metabolic acidosis, rhabdomyolysis, elevated levels of serum
aminotransferase and creatinine, renal failure, and dissemi-
nated intravascular coagulopathy [1]. The onset of symptoms
is usually rapid, and resolution does not occur unless there is
discontinuation of the offending agent(s).
TheHunter criteria aremost widely used for the diagnosis
of this syndrome (84% sensitivity and 97% specificity) [1,
8]. The diagnosis is established if the patient has taken
a serotonergic agent and meets any of the following cri-
teria: spontaneous clonus, inducible clonus plus agitation
or diaphoresis, ocular clonus plus agitation or diaphoresis,
tremor plus hyperreflexia, and hypertonia plus temperature
above 38∘C plus ocular clonus or inducible clonus [8].
Differential diagnoses including anticholinergic poisoning,
malignant hyperthermia, neuroleptic malignant syndrome,
and sympathomimetic toxicity can be distinguished from
serotonin syndrome on the basis of clinical features and
medication history. In our patient, neuroleptic malignant
syndrome was unlikely given the acute nature of symptoms
and the absence of rigidity, hyperthermia, or altered mental
status. Anticholinergic toxicity was unlikely given the pres-
ence of hyperreflexia and the absence of other anticholin-
ergic features. Malignant hyperthermia and other causes of
agitated delirium like CNS infections or sympathomimetic
toxicity were also very unlikely. The rapid resolution of
signs and symptoms after discontinuation of the offending
agents also pointed towards serotonin syndrome as the likely
diagnosis.
Stimulation of the postsynaptic 5-HT1A and 5-HT2A
receptors has been implicated, but this syndrome may result
from any combination of drugs that has the net effect of
increasing serotonergic neurotransmission [1, 9]. The selec-
tive serotonin reuptake inhibitors (SSRIs) are perhaps the
most commonly implicated group of medications associated
with serotonin syndrome. Our patient developed features
of serotonin syndrome after ingestion of higher than pre-
scribed doses of lamotrigine and aripiprazole, in addition to
cocaine abuse. However, none of these agents have strong
serotonergic activity by themselves, and the blood levels
of lamotrigine and aripiprazole in our patient were within
normal limits. These agents do have some effect on serotonin
neurotransmission. Lamotrigine has a weak inhibitory effect
on 5-HT
3
receptor, aripiprazole is partial agonist at 5-HT1A
receptor and an antagonist at serotonin reuptake transporter,
and cocaine increases the release and inhibits the reuptake
of serotonin at the synaptic cleft. Serotonin syndrome in our
patient was most likely caused by the pharmacokinetic and
pharmacodynamic interactions between lamotrigine, arip-
iprazole, and cocaine leading to increased CNS serotonergic
activity.
4. Conclusions
The pharmacokinetic and pharmacodynamic interactions
between lamotrigine, aripiprazole, and cocaine can lead
to increased CNS serotonergic activity. Hence, serotonin
syndrome should be considered in the differential of a
patient who takes these medications and demonstrates even
subtle features of neuromuscular hyperactivity. The manage-
ment of serotonin syndrome includes discontinuation of the
offending agents, supportive care, and benzodiazepines for
symptom control, with serotonin antagonists being a last
resort.
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